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volume and end-diastolic pressure after reperfusion. Group 2 showed increased
expression of myocardial and circulating levels of SDF-1, compared to Group 1.
Myocardial levels of phosphorylated cardioprotective kinases: Akt, ERK, GSK3b and
STAT-3 were increased in Group2, compared to Group 1. TUNEL staining demon-
strated less cardiomyocyte apoptosis and levels of pro-apoptotic factors including
BCL-2 and Caspase-3 were lower in Group 2, compared to Group 1. Compared to
Group 1, the percent myocardial infarct size normalized to the area at risk (AAR) was
reduced in Group 2 (7313% vs 4215%, p¼0.02).
Conclusions: We report the potential beneﬁt of primarily unloading the heart and
delaying coronary reperfusion to salvage myocardium in AMI. This is the ﬁrst report
to demonstrate increased expression of SDF-1 and associated cardioprotective kinases
in response to acute mechanical unloading and delayed myocardial reperfusion. This
report is also the ﬁrst examine the impact of the Impella CP on cardioprotective
signaling in the heart.
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Background: Components of endovascular stents, heart valves and cardiac rhythm
devices are made using metal alloys, which are inherently thrombogenic. We have
developed a robust, hemocompatible plasma-activated coating (PAC) to covalently
bind biomolecules in their bioactive state to metallic surfaces. We then immobilised
plasmin, a major mediator of hemostasis, currently used clinically to disrupt clot
formation, and investigated its blood compatibility.
Methods: PAC was deposited onto stainless steel (SS) substrates in a purpose built
plasma polymerization chamber. Blood compatibility was assessed with heparanized
whole blood in in vitro assays of clotting under rocking and ﬂow conditions, while cell
studies used human coronary artery endothelial cells.
Results: Increasing concentrations of plasmin, 0.1 U, 1.0 U, and 10 U, were
covalently immobilized on PAC. Bioactivity was demonstrated using an established
enzymatic activity assay, while 10U plasmin coating was also found to support
endothelial cell proliferation, increasing 2.6-fold from day 3 to day 5 (p< 0.001). In
a whole blood adhesion assay, these surfaces demonstrated a dramatic reduction of
thrombus weight in a dose dependant manner, compared to SS controls. PAC alone
reduced thrombus weight 45.49.1%, but further reductions were observed for 0.1U
(62.36.4%), 1U (78.36.4%) and 10U (90.51.3%) plasmin, relative to SS (p<
0.001). Strikingly, the 10U plasmin surface signiﬁcantly reduced clot weight
97.71.3% in a modiﬁed chandler loop, relative to SS and PAC alone (p< 0.001).
Moreover, after freeze-drying and 14 weeks of storage, the reduction of thrombus
was persistent (94.68.3%) and not signiﬁcantly different from freshly prepared
surfaces, indicating retention of bioactivity. These ﬁndings were successfully
translated to a custom laser cut SS stent platform, demonstrating robust PAC
adhesion without delamination and similarly striking reductions in thrombus
formation.
Conclusions: Our PAC technology facilitates the covalent immobilization of plasmin,
which dramatically reduced clot formation relative to SS. This has profound potential
to improve the efﬁcacy of all metallic vascular implants, and particularly endovascular
stents.
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Background: Nitrite is a physiologically important nitric oxide (NO) storage inter-
mediate that is reduced to NO during cardiovascular disease states and serves a
cytoprotective function. We evaluated the effects of chronic administration of a novel,
sustained release formulation of sodium nitrite (SR-Nitrite, Theravasc, Inc.) on
circulating NO levels and coronary vascular function in a clinically relevant model of
metabolic syndrome (MetS).
Methods: MetS was generated in Ossabaw miniswine fed an atherosclerotic high-fat
diet (6 months) resulting in profound coronary vascular dysfunction. SR-Nitrite was
administered orally (80 mg/kg b.i.d.) for 3 wks. Plasma levels of nitrite and nitro-
sothiols (RSNO) were quantiﬁed at baseline and following SR-Nitrite. Left anterior
descending coronary arteries were isolated, suspended in organ chambers and iso-
metric tension acquired. Following pre-constriction with PGF2a, vascular relaxation
to sodium nitroprusside was evaluated.
Results: SR-Nitrite therapy increased plasma levels of nitrite (0.35  0.21 vs. 1.2 
0.75 mM; p¼0.02) and RSNO (10.7  2.4 vs. 25.4  5.1 nM; p¼0.03) after 3 wks of
treatment compared to placebo. SR-Nitrite treatment resulted in signiﬁcant improve-
ment in vasoreactivity to SNP with maximal relaxation of 39  10% vs. 72  10 %,
(p< 0.05).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/NeConclusions: In a clinically relevant large animal model of MetS, treatment with SR-
Nitrite increased NO bioavailability and improved ex vivo coronary artery dilation.
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Background: Vascular healing after drug-eluting stent implantation (DES) has been
shown to be an important determinant of PCI-related clinical outcomes. While lag of
endothelialization and increased inﬂammation were reported to cause delayed arterial
healing in ﬁrst generation DES, it has yet to be determined if this relationship also
exists for contemporary DES and fully resorbable everolimus-eluting scaffolds.
Methods: Twenty rabbits received thin-strut bioerodable polymer everolims-eluting
stents (SynergyTM [Boston Scientiﬁc]), thick-strut bioerodable polymer biolimus-
eluting stents (BioMatrixTM [Biosensors]), and thick-strut fully resorbable scaffolds
(Absorb [Abbott Vascular]) in the iliac arteries for 14 and 28 days, respectively (n¼6
for each stent type at 14 days, n¼4 at 28days). Endothelial cell coverage was assessed
using scanning electron microscopy (SEM) and confocal microscopy (CM) following
staining for the endothelial marker CD31/PECAM-1 and RAM11-positive monocytes.
Results: Endothelial coverage was greatest in Synergy (14days, 27%; 28days, 86%)
followed by BioMatrix (14days, 20%; 28days, 65%) and signiﬁcantly less in Absorb
(14 days, 1%; 28 days, 13%) by SEM (14days, P¼0.005; 28days, P¼0.0001,
respectively). The percentage of CD31/PECAM-1 positive endothelial cells above
struts was similar between BioMatrix (17.3%) and Synergy (13.3%), and signiﬁcantly
less in Absorb (0.5%) (P¼0.023), while RAM11 positive macrophage area was
similar between BioMatrix (0.16 mm2) and Synergy (0.17 mm2) and both were
signiﬁcantly less than with Absorb (2.47 mm2) at 28 days (P¼0.0007).
Conclusions: Thin-strut bioerodable polymer everolimus-eluting stents exhibited
superiority with respect to re-endothelialization as compared to thick-strut bioerodable
polymer biolimus-eluting stents and fully resorbable scaffolds, while monocyte
adherence was greatest in the latter. These ﬁndings conﬁrm substantial differences in
vascular healing among contemporary DES and bioresorbable scaffolds.
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Background: Previous preclinical experience showed that polymer-coatings of drug
eluting stents (DES) lower the predisposition for stent thrombosis compared to bare
metal stents. It remains unclear whether relevant differences exist in acute thrombo-
genicity particularly between current permanent and biodegradable polymers used in
clinical practice.
Methods: A porcine ex vivo carotid to jugular arteriovenous shunt model involving a
test circuit of three in-line stents, was used to test thrombogenicity. The permanent
ﬂuoropolymer XIENCE Xpedition everolimus-eluting stent (XIENCE, Abbott
Vascular) (n¼24 stents) was compared with 4 CE-marked DES with biodegradable
polymer coatings i) BioMatrix Flex (Biosensors) ii) Nobori (Terumo), iii) Orsiro
(Biotronik AG), and iv) Synergy (Boston Scientiﬁc) (n¼6 each). After 1h of cir-
culation, platelet adherence in whole mount stents was identiﬁed by immunoﬂuo-
rescent staining against dual platelet markers (CD61/CD42b) and imaged and
quantiﬁed under confocal microscopy.
Results: XIENCE showed the least area occupied by thrombus compared to the other
4 DES, with a signiﬁcant difference compared to BioMatrix Flex (p< 0.001) and
Synergy (p< 0.001) (Figure). The number of platelet aggregation clots was also thew Devices and Innovation B127
